{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T05:56:13Z","timestamp":1791093373817,"version":"4.1.0"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1097\/jcp.0b013e31823657d9","type":"journal-article","created":{"date-parts":[[2011,10,21]],"date-time":"2011-10-21T04:09:11Z","timestamp":1319170151000},"page":"698-704","source":"Crossref","is-referenced-by-count":28,"title":["A Review and Bayesian Meta-Analysis of Clinical Efficacy and Adverse Effects of 4 Atypical Neuroleptic Drugs Compared With Haloperidol and Placebo"],"prefix":"10.1097","volume":"31","author":[{"given":"Marianne","family":"Klemp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingunn Fride","family":"Tvete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tor","family":"Skomedal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f8rund","family":"Gaasemyr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bent","family":"Natvig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivar","family":"Aursnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-4-20210128","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1080\/14017430310001186","article-title":"Clinical efficacies of antihypertensive drugs.","volume":"37","author":"Aursnes","year":"2003","journal-title":"Scand Cardiovasc J"},{"key":"R2-4-20210128","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1176\/appi.ajp.158.8.1305","article-title":"A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia.","volume":"158","author":"Azorin","year":"2001","journal-title":"Am J Psychiatry"},{"key":"R3-4-20210128","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.4088\/JCP.v64n1110","article-title":"Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study.","volume":"64","author":"Bai","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"R4-4-20210128","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0893-133X(95)00069-P","article-title":"Olanzapine versus placebo and haloperidol - Acute phase results of the North American double-blind olanzapine trial.","volume":"14","author":"Beasley","year":"1996","journal-title":"Neuropsychopharmacology"},{"key":"R5-4-20210128","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/BF02245617","article-title":"Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial.","volume":"124","author":"Beasley","year":"1996","journal-title":"Psychopharmacology"},{"key":"R6-4-20210128","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.pnpbp.2003.09.033","article-title":"Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia.","volume":"28","author":"Bitter","year":"2004","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R7-4-20210128","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1176\/ajp.155.4.499","article-title":"Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study.","volume":"155","author":"Bondolfi","year":"1998","journal-title":"Am J Psychiatry"},{"key":"R9-4-20210128","doi-asserted-by":"crossref","first-page":"29","DOI":"10.4088\/JCP.v68n0104","article-title":"Efficacy and safety of aripiprazole in the acute treatment of schizophrenia in Chinese patients with risperidone as an active control: a randomized trial.","volume":"68","author":"Chan","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"R10-4-20210128","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/00004714-199302000-00004","article-title":"A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.","volume":"13","author":"Chouinard","year":"1993","journal-title":"J Clin Psychopharmacol"},{"key":"R11-4-20210128","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1176\/appi.ajp.158.5.765","article-title":"A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder.","volume":"158","author":"Conley","year":"2001","journal-title":"Am J Psychiatry"},{"key":"R12-4-20210128","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.4088\/JCP.v67n1004","article-title":"A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis.","volume":"67","author":"Crespo-Facorro","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"R13-4-20210128","first-page":"691","article-title":"The efficacy and safety of lower doses of aripiprazole for the treatment of patients with acute exacerbation of schizophrenia.","volume":"11","author":"Cutler","year":"2006","journal-title":"Int J Neuropsychiatr Med"},{"key":"R14-4-20210128","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1176\/appi.ajp.2008.07061035","article-title":"A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia.","volume":"165","author":"Findling","year":"2008","journal-title":"Am J Psychiatry"},{"key":"R15-4-20210128","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0920-9964(02)00226-8","article-title":"Olanzapine vs risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand.","volume":"61","author":"Gureje","year":"2003","journal-title":"Schizophr Res"},{"key":"R16-4-20210128","doi-asserted-by":"crossref","first-page":"763","DOI":"10.4088\/JCP.v63n0903","article-title":"Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.","volume":"63","author":"Kane","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"R17-4-20210128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2005.07.038","article-title":"One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia.","volume":"81","author":"Keefe","year":"2006","journal-title":"Schizophr Res"},{"key":"R18-4-20210128","first-page":"224S","article-title":"A double-blind, placebo-controlled study of olanzapine in adolescents with schizophrenia.","volume":"59","author":"Kryzhanovskaya","year":"2006","journal-title":"Biol Psychiatry"},{"key":"R19-4-20210128","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1600-0447.2006.00887.x","article-title":"The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial.","volume":"114","author":"Lecrubier","year":"2006","journal-title":"Acta Psychiatr Scand"},{"key":"R20-4-20210128","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1176\/appi.ajp.160.8.1396","article-title":"Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol.","volume":"160","author":"Lieberman","year":"2003","journal-title":"Am J Psychiatry"},{"key":"R21-4-20210128","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1176\/ajp.151.6.825","article-title":"Risperidone in the treatment of schizophrenia.","volume":"151","author":"Marder","year":"1994","journal-title":"Am J Psychiatry"},{"key":"R22-4-20210128","first-page":"47","article-title":"A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.","volume":"65","author":"McQuade","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"R24-4-20210128","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/archpsyc.60.7.681","article-title":"Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.","volume":"60","author":"Potkin","year":"2003","journal-title":"Arch Gen Psychiatry"},{"key":"R25-4-20210128","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.schres.2006.03.027","article-title":"A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization.","volume":"85","author":"Potkin","year":"2006","journal-title":"Schizophr Res"},{"key":"R26-4-20210128","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1176\/ajp.2006.163.12.2096","article-title":"Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes.","volume":"163","author":"Robinson","year":"2006","journal-title":"Am J Psychiatry"},{"key":"R27-4-20210128","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJM199709183371202","article-title":"A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia.","volume":"337","author":"Rosenheck","year":"1997","journal-title":"N Engl J Med"},{"key":"R28-4-20210128","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1176\/ajp.154.4.466","article-title":"Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine.","volume":"154","author":"Tollefson","year":"1997","journal-title":"Am J Psychiatry"},{"key":"R29-4-20210128","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/S0006-3223(00)01026-X","article-title":"Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine.","volume":"49","author":"Tollefson","year":"2001","journal-title":"Biol Psychiatry"},{"key":"R30-4-20210128","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/00004714-199710000-00010","article-title":"Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.","volume":"17","author":"Tran","year":"1997","journal-title":"J Clin Psychopharmacol"},{"key":"R31-4-20210128","first-page":"341","article-title":"Symptom response and side-effects of olanzapine and risperidone in young adults with recent onset schizophrenia.","volume":"18","author":"van Bruggen","year":"2003","journal-title":"Int Clin Psychopharmacol"},{"key":"R32-4-20210128","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/S0140-6736(09)60046-5","article-title":"Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis.","volume":"373","author":"Cipriani","year":"2009","journal-title":"Lancet"},{"key":"R33-4-20210128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2010.05.025","article-title":"Schizophrenia, \"just the facts.\" 5. Treatment and prevention past, present, and future.","volume":"122","author":"Tandon","year":"2010","journal-title":"Schizophr Res"},{"key":"R34-4-20210128","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1176\/appi.ajp.2008.08030368","article-title":"A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia.","volume":"166","author":"Leucht","year":"2009","journal-title":"Am J Psychiatry"},{"key":"R35-4-20210128","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/sj.mp.4002136","article-title":"How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials.","volume":"14","author":"Leucht","year":"2009","journal-title":"Mol Psychiatry"},{"key":"R36-4-20210128","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis.","volume":"373","author":"Leucht","year":"2009","journal-title":"Lancet"},{"key":"R37-4-20210128","first-page":"1","article-title":"Aripiprazole versus other atypical antipsychotics for schizophrenia.","volume":"4","author":"Komossa","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"R38-4-20210128","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.schres.2010.07.012","article-title":"Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis.","volume":"123","author":"Rummel-Kluge","year":"2010","journal-title":"Schizophr Res"},{"key":"R40-4-20210128","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1136\/bmj.319.7208.508","article-title":"Methods in health service research: an introduction to Bayesian methods in health technology assessment.","volume":"319","author":"Spiegelhalter","year":"1999","journal-title":"Br Med J"},{"key":"R41-4-20210128","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1023\/A:1008929526011","article-title":"WinBUGS-a Bayesian modelling framework: concepts, structure, and extensibility.","volume":"10","author":"Lunn","year":"2000","journal-title":"Stat Comput"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00004714-201112000-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:24:18Z","timestamp":1786047858000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00004714-201112000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0b013e31823657d9","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}